What did Culper Research allege about ADMA Biologics?

Culper Research published a short report alleging misconduct at ADMA Biologics, which management characterized as "unsubstantiated, misleading and inaccurate." The specific allegations center on channel dynamics and revenue quality — claims consistent with ADMA's financial profile of -$18mn FCF on 57.4% gross margins and a -36.4% Q4 EPS miss following three consecutive quarterly beats. ADMA's shares initially fell sharply before rebounding 11.6% on the company's denial.

Why did Cantor Fitzgerald downgrade ADMA Biologics before the Culper short report dropped?

Cantor Fitzgerald cut ADMA to Neutral from Overweight one day before Culper published, suggesting the firm's channel checks or fundamental analysis had already surfaced the same concerns Culper later made public. Sell-side analysts communicate through rating changes when they cannot otherwise speak — this sequencing is a tell that institutional awareness of fundamental deterioration predated the short report by at least one trading day.

Why is ADMA Biologics generating negative free cash flow despite 57% gross margins?

ADMA generated -$18mn in FCF on $510mn revenue with 57.4% gross margins — a structural anomaly. A company with this margin profile should generate $50-80mn in FCF under normal operating conditions. The gap implies $70-100mn in cash consumption below the gross profit line from capex, capitalized costs, or working capital build. Working capital build consistent with channel inventory accumulation is one explanation the Culper report and Q4 earnings miss together make plausible, though management has not provided a full accounting of the discrepancy.

What does ADMA's Q4 2025 earnings miss signal about revenue recognition risk?

ADMA posted $0.11 in EPS vs. a $0.165 estimate — a -36.4% miss — after three consecutive quarterly beats. That cadence is consistent with pull-forward revenue recognition: shipments recorded as revenue earlier in the year, followed by a hard quarter when sell-through fails to keep pace with shipments. If correct, the 18.4% YoY revenue growth figure is not a reliable forward run-rate, and estimates underpinning the 6.6x forward PE are overstated — making the multiple expand on earnings compression rather than contract.

Is ADMA Biologics worth buying after the short seller attack?

At 6.6x forward earnings and $9.15, ADMA appears cheap — but only if the forward earnings estimate is accurate. The -$18mn FCF on 57% gross margins, the Cantor pre-report downgrade, and the Q4 miss pattern collectively raise credible doubt about whether the E in that multiple reflects economic reality. The risk/reward does not favor initiating long exposure until Q1 2025 data on accounts receivable and inventory levels clarifies whether Q4 was a timing anomaly or the beginning of a structural normalization.

ADMAMarch 31, 2026

By Basis Report Editorial · Updated April 1, 2026

ADMA Biologics Cracks: -$18mn Free Cash Flow Betrays 57% Gross Margin

NEW YORK, March 31 —

Cantor Fitzgerald downgraded ADMA Biologics (ADMA) to Neutral from Overweight one day before Culper Research published its short report. ADMA's longest-standing institutional supporter was out the door before the short sellers arrived. Three consecutive EPS beats in Q1 through Q3, then a sudden -36.4% Q4 miss: that sequence points to a revenue recognition problem, not a one-quarter stumble. If the Q4 miss is structural, the 6.6x forward PE that consensus calls a value floor is a value trap.

What the Street Believes

Consensus sits at a $23.50 price target against a $9.15 current price — +157% above current levels. The bull thesis rests on ADMA's plasma immunoglobulin franchise: end-to-end collection and manufacturing control, plus an FDA-regulated supply chain that takes years to replicate. Demand for immunoglobulin therapies consistently outstrips supply, giving ADMA durable pricing power. The operating leverage argument: fixed processing costs get absorbed as revenue scales past $500mn, and free cash flow turns sharply positive. The stock shed roughly 45% since last earnings. Consensus landed on a straightforward read — the fundamentals are intact and the selloff went too far.

That read is not absurd. ADMA posted 18.4% YoY revenue growth and 57.4% gross margins — a specialty pharma business with a protected supply chain and expanding margins. Consensus is betting Q4 was noise and that 2025 returns to double-digit revenue growth. The problem: the street is taking management's characterization of Q4 at face value. No one has independently confirmed whether 18.4% growth is a sustainable run-rate or the peak of a recognition cycle. At $9.15, that distinction is worth roughly $14 of stock price.

What the Data Shows

The street expects 57% gross margins to translate into strong free cash flow. The data shows -$18mn in free cash flow on $510mn in revenue. That gap does not close without a specific explanation — capex intensity, capitalized costs, or working capital build — and the magnitude demands one. A specialty pharma company at this margin profile and revenue scale should generate $50-80mn in FCF, even with heavy reinvestment. The -$18mn actual figure implies $70-100mn in cash consumed below the gross profit line by items not fully visible in reported earnings. That is the pattern of channel inventory accumulation, aggressive revenue pull-forward, or both. Either answer guts the forward earnings estimates the 6.6x PE multiple rests on.

"ADMA Biologics issues statement refuting 'unsubstantiated, misleading and inaccurate allegations by Culper Research' — while Cantor Fitzgerald had already downgraded to Neutral from Overweight the prior day, before the short report dropped."

The statement is noise. The timing is signal. Culper's channel-stuffing thesis fits the data: three quarters of beats building inventory through the distribution chain, then a -36.4% Q4 miss as sell-through failed to keep pace with shipments. If 18.4% YoY revenue growth reflects the peak of a recognition cycle rather than the base of a durable franchise ramp, forward estimates are overstated. On compressed earnings, 6.6x reported PE becomes 10-12x actual PE — no longer cheap, no longer a credible floor.

Why This Changes the Calculus

The model breaks at the FCF line. Test the operating leverage thesis against -$18mn FCF and two conclusions emerge. Either below-the-line cash consumption is structural and permanent — which kills the leverage thesis — or it normalizes and free cash flow turns positive. The second path follows the same logic as a revenue cash burn story: the multiple looks cheap until working capital unwinds and true earnings power becomes clear. The -$18mn FCF figure also fits a simpler explanation. ADMA's plasma collection and fractionation infrastructure carries high fixed costs. If utilization rates don't yet cover the full cost stack, cash burns even as margins look healthy on paper. That argument requires believing capex and working capital investment are temporary. The data does not support that read.

The more uncomfortable parallel: margin compression at scale does not announce itself in gross profit. It shows up in FCF first, and by the time it hits the income statement, the stock has already repriced. ADMA's gross margin is 57%. Its FCF margin is negative. That spread is not a rounding error; it is either a temporary cash drag or evidence that the business does not convert margin to cash at this revenue scale. The Q4 miss makes the structural case harder to dismiss.